FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to an indole compound of formula (I), where the values Y, Z, R1-R6, m, n are defined in the claim, its pharmaceutical composition and use as a decreasing regulator of estrogen receptors in preparing drugs for treating estrogen-receptor-positive breast cancer.
EFFECT: disclosed are substituted indole compounds as reducing regulators of estrogen receptors.
21 cl, 5 tbl, 65 ex
Title | Year | Author | Number |
---|---|---|---|
THIENODIAZEPINE DERIVATIVES AND THEIR USE | 2018 |
|
RU2795005C2 |
CDK4/6 INHIBITOR | 2017 |
|
RU2747311C2 |
DERIVATIVE BASED ON DIHYDROPYRIMIDO-RING AS HBV INHIBITOR | 2015 |
|
RU2693897C2 |
QUINOLINE DERIVATIVES AS SMO INHIBITORS | 2015 |
|
RU2695815C2 |
FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
INHIBITOR OF EGFR AND PRODUCTION AND USE THEREOF | 2015 |
|
RU2702631C2 |
PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | 2017 |
|
RU2711991C1 |
PYRAZINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2809631C2 |
TAXANE COMPOUNDS AND ALSO THE PRODUCTION METHOD AND USE THEREOF | 2014 |
|
RU2686675C1 |
PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS AN MTOR/PI3K INHIBITOR | 2015 |
|
RU2658912C1 |
Authors
Dates
2020-06-01—Published
2017-03-24—Filed